search
Back to results

Hymovis® Intra-articular Injections vs Corticosteroids Intra-articular Injections in Patients Affected by Glenohumeral Osteoarthritis:

Primary Purpose

Glenohumeral Osteoarthritis

Status
Completed
Phase
Phase 4
Locations
Italy
Study Type
Interventional
Intervention
Hyaluronic Acid 24 MG in 3 mL Prefilled Syringe
Corticosteroid injection
Sponsored by
Concordia Hospital Rome
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Glenohumeral Osteoarthritis focused on measuring Osteoarthritis, Hyaluronic Acid, Corticosteroids

Eligibility Criteria

40 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male or female patient aged ≥40 years Patient suffering from glenohumeral osteoarthritis with chronic shoulder pain. Chronic shoulder pain is defined as follows: Persistence for a period of at least 6 months, but not more than 5 years; Pain perceived by the patient with a frequency of at least 50% of the days in the month preceding the inclusion visit; Kellgren-Lawrence grade of 2 or 3 in the glenohumeral joint confirmed by x-ray exam performed within 3 months prior to the inclusion visit. Presence, at baseline, of pain on movement, in the shoulder under study, measured by VAS with a score between 40 and 80 mm Presence at baseline of pain in the contralateral shoulder at least 10mm less than the study shoulder and no more than 40mm as measured by VAS at the inclusion visit Presence, at baseline, of limitation of shoulder motion in at least one direction in the following ranges of motion: Fixed scapula abduction ≤ 80° Internal rotation in abduction ≤ 55° External rotation in abduction ≤ 80° These shoulder limitations are for normal expected excursions. Patient who has not responded adequately to non-pharmacological conservative therapy and to taking simple analgesics Patient willing to sign and able to understand the Informed Consent form Patient who is not pregnant or nursing. Women of childbearing potential (including women who have been less than one year postmenopausal) must agree to use reliable contraception for the duration of the study. Exclusion Criteria: Presence, on clinical evaluation, of adhesive capsulitis Evidence of rotator cuff injury Presence of primary extra-articular shoulder syndromes (eg impingement, bursitis, tendonitis) Evidence of clinically significant shoulder deformity Signs, evident on X-ray radiography of the shoulder, of recent fractures, severe loss of bone density and/or severe deformity Diagnosed with crystal deposition disease of calcium pyrophosphate dihydrate (CPPD) or chondrocalcinosis of the shoulder Presence of pathology of the cervical vertebrae (able to alter the clinical evaluation) which, in the three months preceding the inclusion visit, was symptomatic and required active treatment Presence of any active musculoskeletal disease affecting the diagnosis/evaluation of shoulder pain or presence of pain of any neurological etiology and acute shoulder infection Presence of major surgery, arthroplasty or arthroscopy in the shoulder under study in the 6 months prior to inclusion and/or surgery planned during the study Patient undergoing local radiotherapy for breast cancer Patient with polymyalgia rheumatica History of skin cancer (except basal cell carcinoma) treated for less than two years History of severe recurrent or immune-mediated allergic reactions Presence of infection and/or skin pathologies in the injection area; psoriasis Presence of serious gastrointestinal, renal, hepatic, pulmonary, cardiovascular, neurological disorders that could interfere with the study results or patient's inability to comply with the study requirements Known allergy or suspected allergic reactions to hyaluronate or corticosteroid preparations Taking HA products intra-articularly in the month preceding the inclusion visit Taking bisphosphonates and/or pharmaceutical products taken orally and containing glucosamine and/or chondroitin sulphate and/or diacerin (eg Chondrosulf, Structum 500, Dona, Viatril, Fisiodar, Artrodar, etc.) in the month preceding the inclusion visit unless the dosage was stable in the two months prior to the inclusion visit Intra-articular corticosteroid injections in the study shoulder in the three months preceding the inclusion visit Intra-articular corticosteroid injections in any joint in the month preceding the inclusion Taking oral corticosteroids in the month prior to the inclusion visit (only inhaled corticosteroids are permitted) Previous use of HA in the study shoulder within 6 months prior to inclusion Changed physical therapy in the month prior to inclusion visit or unwillingness to maintain stable regimen Patient with history of thyroid insufficiency Patient being treated with anticoagulant therapy Patient on phenobarbital treatment prior to study inclusion Taking analgesic therapies (NSAIDs, opioid analgesics, topical analgesics) for any condition that could interfere with the evaluation of the shoulder under study Intake of another experimental product in the month preceding the inclusion visit Patient who, in the opinion of the investigator, is unwilling to comply with study procedures or will not cooperate during the course of the study Pregnant or breastfeeding woman

Sites / Locations

  • Concordia Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Treatment group

Control group

Arm Description

patients shoulder treated with Hymovis® 24mg/3ml.

patients shoulder treated with Corticosteroid.

Outcomes

Primary Outcome Measures

Evaluate the pain reduction in the target shoulder compared to control group
Changes of pain on movement in the target shoulder, evaluated with a 0-100 mm Visual Analogue Scale (VAS) values compared to baseline (V1).

Secondary Outcome Measures

Evaluation of the Quality of Life of the patients
Changes of patient's quality of life, evaluated by administration of the EuroQol 5-Dimension Questionnaire (EQ-5D-5L) compared to baseline (V1)
Evaluate the amelioration of shoulder functionality
Clinical functional assessment on movement from baseline (V1), measured by Constant Murley (CMS) shoulder test ;
Evaluate the pain reduction in the target shoulder compared to baseline
Changes of pain on movement in the target shoulder, evaluated with a 0-100 mm Visual Analogue Scale (VAS) values compared to baseline (V1).
Evaluation of the safety of the treatment
Safety of Hymovis® were evaluated in terms of incidence of treatment-emergent adverse events (TEAEs) over the investigational period.

Full Information

First Posted
August 29, 2023
Last Updated
September 12, 2023
Sponsor
Concordia Hospital Rome
search

1. Study Identification

Unique Protocol Identification Number
NCT06043544
Brief Title
Hymovis® Intra-articular Injections vs Corticosteroids Intra-articular Injections in Patients Affected by Glenohumeral Osteoarthritis:
Official Title
Hymovis® Intra-articular Injections vs Corticosteroids Intra-articular Injections in Patients Affected by Glenohumeral Osteoarthritis: a Monocentric Randomized Open-label Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
May 2, 2021 (Actual)
Primary Completion Date
November 10, 2021 (Actual)
Study Completion Date
March 31, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Concordia Hospital Rome

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
This monocentric randomized open-label study aims to assess the efficacy and safety of a treatment with medium molecular weight hyaluronic acid (HA) compared to a treatment with corticosteroids on patients affected by glenohumeral osteoarthritis.
Detailed Description
Glenohumeral osteoarthritis (OA) is a very common joint disease characterized by pain and functional limitation. No standardized protocols of treatment are available in clinical practice and literature data are confusing. This monocentric randomized open-label study aims to assess the efficacy and safety of a treatment with medium molecular weight hyaluronic acid (HA) compared to a treatment with corticosteroids on patients affected by glenohumeral osteoarthritis. A total of 80 consecutive patients with glenohumeral OA (Kellegren Lawrence degree II or III) were randomized in two different groups, intto Hymovis® (24mg/3ml) (treatment group) or into corticosteroids (control group), with a follow-up after 3 and 6 months. Modifications in terms of pain (VAS), range of motion (ROM) and quality of life (EQ-5D) were observed during the treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glenohumeral Osteoarthritis
Keywords
Osteoarthritis, Hyaluronic Acid, Corticosteroids

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
80 consecutive patients with glenohumeral OA degree II or III were prospectively enrolled in our clinic from May 2021 to March 2022. The study was approved by Concordia Hospital Ethical Committee (02/2021) and performed according to ISO14155:2020 and Declaration of Helsinki.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment group
Arm Type
Experimental
Arm Description
patients shoulder treated with Hymovis® 24mg/3ml.
Arm Title
Control group
Arm Type
Active Comparator
Arm Description
patients shoulder treated with Corticosteroid.
Intervention Type
Device
Intervention Name(s)
Hyaluronic Acid 24 MG in 3 mL Prefilled Syringe
Intervention Description
Patients in the treatment group received two intra-articular injections with Hymovis® (24mg/3ml) a week apart from each other
Intervention Type
Drug
Intervention Name(s)
Corticosteroid injection
Intervention Description
Patients in control group received two intra-articular injections with corticosteroids a week apart from each other.
Primary Outcome Measure Information:
Title
Evaluate the pain reduction in the target shoulder compared to control group
Description
Changes of pain on movement in the target shoulder, evaluated with a 0-100 mm Visual Analogue Scale (VAS) values compared to baseline (V1).
Time Frame
At 6 months
Secondary Outcome Measure Information:
Title
Evaluation of the Quality of Life of the patients
Description
Changes of patient's quality of life, evaluated by administration of the EuroQol 5-Dimension Questionnaire (EQ-5D-5L) compared to baseline (V1)
Time Frame
At 6 months
Title
Evaluate the amelioration of shoulder functionality
Description
Clinical functional assessment on movement from baseline (V1), measured by Constant Murley (CMS) shoulder test ;
Time Frame
At 6 months
Title
Evaluate the pain reduction in the target shoulder compared to baseline
Description
Changes of pain on movement in the target shoulder, evaluated with a 0-100 mm Visual Analogue Scale (VAS) values compared to baseline (V1).
Time Frame
At 6 months
Title
Evaluation of the safety of the treatment
Description
Safety of Hymovis® were evaluated in terms of incidence of treatment-emergent adverse events (TEAEs) over the investigational period.
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female patient aged ≥40 years Patient suffering from glenohumeral osteoarthritis with chronic shoulder pain. Chronic shoulder pain is defined as follows: Persistence for a period of at least 6 months, but not more than 5 years; Pain perceived by the patient with a frequency of at least 50% of the days in the month preceding the inclusion visit; Kellgren-Lawrence grade of 2 or 3 in the glenohumeral joint confirmed by x-ray exam performed within 3 months prior to the inclusion visit. Presence, at baseline, of pain on movement, in the shoulder under study, measured by VAS with a score between 40 and 80 mm Presence at baseline of pain in the contralateral shoulder at least 10mm less than the study shoulder and no more than 40mm as measured by VAS at the inclusion visit Presence, at baseline, of limitation of shoulder motion in at least one direction in the following ranges of motion: Fixed scapula abduction ≤ 80° Internal rotation in abduction ≤ 55° External rotation in abduction ≤ 80° These shoulder limitations are for normal expected excursions. Patient who has not responded adequately to non-pharmacological conservative therapy and to taking simple analgesics Patient willing to sign and able to understand the Informed Consent form Patient who is not pregnant or nursing. Women of childbearing potential (including women who have been less than one year postmenopausal) must agree to use reliable contraception for the duration of the study. Exclusion Criteria: Presence, on clinical evaluation, of adhesive capsulitis Evidence of rotator cuff injury Presence of primary extra-articular shoulder syndromes (eg impingement, bursitis, tendonitis) Evidence of clinically significant shoulder deformity Signs, evident on X-ray radiography of the shoulder, of recent fractures, severe loss of bone density and/or severe deformity Diagnosed with crystal deposition disease of calcium pyrophosphate dihydrate (CPPD) or chondrocalcinosis of the shoulder Presence of pathology of the cervical vertebrae (able to alter the clinical evaluation) which, in the three months preceding the inclusion visit, was symptomatic and required active treatment Presence of any active musculoskeletal disease affecting the diagnosis/evaluation of shoulder pain or presence of pain of any neurological etiology and acute shoulder infection Presence of major surgery, arthroplasty or arthroscopy in the shoulder under study in the 6 months prior to inclusion and/or surgery planned during the study Patient undergoing local radiotherapy for breast cancer Patient with polymyalgia rheumatica History of skin cancer (except basal cell carcinoma) treated for less than two years History of severe recurrent or immune-mediated allergic reactions Presence of infection and/or skin pathologies in the injection area; psoriasis Presence of serious gastrointestinal, renal, hepatic, pulmonary, cardiovascular, neurological disorders that could interfere with the study results or patient's inability to comply with the study requirements Known allergy or suspected allergic reactions to hyaluronate or corticosteroid preparations Taking HA products intra-articularly in the month preceding the inclusion visit Taking bisphosphonates and/or pharmaceutical products taken orally and containing glucosamine and/or chondroitin sulphate and/or diacerin (eg Chondrosulf, Structum 500, Dona, Viatril, Fisiodar, Artrodar, etc.) in the month preceding the inclusion visit unless the dosage was stable in the two months prior to the inclusion visit Intra-articular corticosteroid injections in the study shoulder in the three months preceding the inclusion visit Intra-articular corticosteroid injections in any joint in the month preceding the inclusion Taking oral corticosteroids in the month prior to the inclusion visit (only inhaled corticosteroids are permitted) Previous use of HA in the study shoulder within 6 months prior to inclusion Changed physical therapy in the month prior to inclusion visit or unwillingness to maintain stable regimen Patient with history of thyroid insufficiency Patient being treated with anticoagulant therapy Patient on phenobarbital treatment prior to study inclusion Taking analgesic therapies (NSAIDs, opioid analgesics, topical analgesics) for any condition that could interfere with the evaluation of the shoulder under study Intake of another experimental product in the month preceding the inclusion visit Patient who, in the opinion of the investigator, is unwilling to comply with study procedures or will not cooperate during the course of the study Pregnant or breastfeeding woman
Facility Information:
Facility Name
Concordia Hospital
City
Rome
ZIP/Postal Code
00145
Country
Italy

12. IPD Sharing Statement

Learn more about this trial

Hymovis® Intra-articular Injections vs Corticosteroids Intra-articular Injections in Patients Affected by Glenohumeral Osteoarthritis:

We'll reach out to this number within 24 hrs